Eiger BioPharmaceuticals, Inc. (EIGR): Price and Financial Metrics


Eiger BioPharmaceuticals, Inc. (EIGR)

Today's Latest Price: $9.96 USD

0.18 (1.84%)

Updated Oct 22 4:00pm

Add EIGR to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

EIGR Stock Price Chart Interactive Chart >

Price chart for EIGR

EIGR Price/Volume Stats

Current price $9.96 52-week high $15.82
Prev. close $9.78 52-week low $4.55
Day low $9.64 Volume 310,800
Day high $10.13 Avg. volume 413,337
50-day MA $10.01 Dividend yield N/A
200-day MA $10.07 Market Cap 291.26M

Eiger BioPharmaceuticals, Inc. (EIGR) Company Bio

Eiger BioPharmaceutical Inc, formerly Celladon Corporation, is a clinical-stage biotechnology company engaged in the development of cardiovascular gene therapy. The company was founded in 2008 and is based in Palo Alto, California.

Most Popular Stories View All

• Dangerous Outlook for Stocks Into Election

• Forget FAAMG, Buy These 4 Top Stocks Instead

• Is Electric Vehicle Stock Workhorse Group a Buy at $20?

• 4 Innovative ETFs to SUPERPOWER Your Portfolio in 2021

• Aurora Cannabis vs. Canopy Growth: Which Stock is a Better Buy?

View All Top Stories

EIGR Latest News Stream

Event/Time News Detail
Loading, please wait...
View All EIGR News

EIGR Latest Social Stream

Loading social stream, please wait...

View Full EIGR Social Stream

Latest EIGR News From Around the Web

Below are the latest news stories about Eiger BioPharmaceuticals Inc that investors may wish to consider to help them evaluate EIGR as an investment opportunity.

Eiger BioPharmaceuticals COVID-19 Study Fails to Live Up to Expectations

No summary available.

24/7 Wall street | September 28, 2020

Eiger: Upcoming Catalysts And Platform Make It A Buy

Eiger BioPharmaceuticals, Inc. (EIGR) is on the verge of commercial breakthrough with a near-certain approval in November 2020 of their first product candidate lonafarnib in progeria. This approval will pave the way for a priority review of its next combo-therapy for Hepatitis D Virus ((HDV)) with the same drug candidate,...

Avisol Capital Partners on Seeking Alpha | September 23, 2020

Coronavirus Pandemic: Regeneron And Eiger BioPharmaceuticals Positioned To Benefit From Opportunity In Treating Early Stage And At-Risk Patients

The coronavirus pandemic has proved more difficult to contain in the US than was expected. I attribute this to the virus's contagion and virulence coupled with several states relaxing restrictions too early and to too great of an extent. As we try to forecast the course of events, several possibilities...

Leonard Yaffe on Seeking Alpha | July 22, 2020

Is Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Popular Amongst Institutions?

Every investor in Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) should be aware of the most powerful shareholder...

Yahoo | July 17, 2020

Did Hedge Funds Make The Right Call On Eiger BioPharmaceuticals, Inc. (EIGR) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 13, 2020

Read More 'EIGR' Stories Here

EIGR Price Returns

1-mo 6.87%
3-mo -2.54%
6-mo 23.73%
1-year 0.10%
3-year -9.45%
5-year N/A
YTD -33.15%
2019 46.65%
2018 -27.17%
2017 19.74%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8619 seconds.